vTv Therapeutics (NASDAQ:VTVT) Posts Quarterly Earnings Results

vTv Therapeutics (NASDAQ:VTVT) posted its quarterly earnings results on Thursday. The biotechnology company reported ($0.94) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.15, FiscalAI reports.

vTv Therapeutics Price Performance

Shares of vTv Therapeutics stock traded down $2.29 during trading hours on Thursday, hitting $21.74. The company’s stock had a trading volume of 17,774 shares, compared to its average volume of 51,027. vTv Therapeutics has a 12 month low of $21.72 and a 12 month high of $44.00. The stock has a 50 day moving average of $29.70 and a 200 day moving average of $33.36. The company has a market capitalization of $85.63 million, a PE ratio of -20.51 and a beta of 0.28.

Analysts Set New Price Targets

A number of research firms recently commented on VTVT. Lifesci Capital upgraded vTv Therapeutics to a “strong-buy” rating in a report on Wednesday, September 2nd. BTIG Research reaffirmed a “buy” rating and issued a $57.00 price target on shares of vTv Therapeutics in a research note on Wednesday, October 14th. Wall Street Zen downgraded shares of vTv Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, October 24th. HC Wainwright reduced their price objective on shares of vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Finally, Weiss Ratings cut shares of vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $55.83.

About vTv Therapeutics

vTv Therapeutics Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and neurological diseases. The company uses small-molecule drug discovery and development programs to address conditions with significant unmet medical needs.

Its lead product candidate is TTP399, an oral, liver-selective glucokinase activator being developed as an adjunctive treatment for people with type 1 diabetes. The company has also developed other investigational therapies, including compounds targeting type 2 diabetes, obesity and Alzheimer’s disease.